Monocyte targeting and activation by cationic liposomes formulated with a TLR7 agonist

Bibliography

• Ahsan F, Rivas IP, Khan MA, et al. Targeting to macrophages: role of physicochemical properties of particulate carriers—liposomes and microspheres—on the phagocytosis by macrophages. J control release 2002;79(1):29-40
   PubMed Web of Science ®Google Scholar
• Kelly C, Jefferies C, Cryan SA. Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv 2011;2011:Article ID 727241; 1-11
   Google Scholar
• Serbina NV, Jia T, Hohl TM, et al. Monocyte-mediated defense against microbial pathogens. Annu Rev Immunol 2008;26:421-52
   PubMed Web of Science ®Google Scholar
• Chonn A, Cullis PR, Devine DV. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J Immunol 1991;146(12):4234-41
   PubMed Web of Science ®Google Scholar
• Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol 2011;11(11):762-74
   PubMed Web of Science ®Google Scholar
• Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009;27:669-92
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013;39(1):38-48
   PubMed Web of Science ®Google Scholar
• Ueno H, Klechevsky E, Schmitt N, et al. Targeting human dendritic cells subsets for improved vaccines. Semin Immunol 2011;23(1):21-7
   PubMed Web of Science ®Google Scholar
• Tacken PJ, Torensma R, Figdor CG. Targeting antigens to dendritic cells in vivo. Immunobiology 2006;211(6-8):599-608
   PubMed Web of Science ®Google Scholar
• Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer 2013;13(10):739-52
   PubMed Web of Science ®Google Scholar
• Batzri S, Korn ED. Single bilayer liposomes prepared without sonication. Biochim Biophys Acta 1973;298(4):1015-19
   PubMed Web of Science ®Google Scholar
• Zucker D, Jensen SS, Pourhassan H, et al. Targeting and activation of monocytes by liposomes with TLR7- adjuvants. Biomaterial 2014; Submitted
   Google Scholar
• Jensen SS, Gad M. Differential induction of inflammatory cytokines by dendritic cells treated with novel TLR-agonist and cytokine based cocktails: targeting dendritic cells in autoimmunity. J Inflamm 2010;7:37
   Google Scholar
• Leuschner F, Dutta P, Gorbatov R, et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 2011;29(11):1005-10
   PubMed Web of Science ®Google Scholar
• Karathanasis E, Geigerman CM, Parkos CA, et al. Selective targeting of nanocarriers to neutrophils and monocytes. Ann Biomed Eng 2009;37(10):1984-92
   PubMed Web of Science ®Google Scholar
• Dandamudi S, Campbell RB. Development and characterization of magnetic cationic liposomes for targeting tumor microvasculature. Biochim Biophys Acta 2007;1768(3):427-38
   PubMed Web of Science ®Google Scholar
• Romberg B, Hennink WE, Storm G. Sheddable coatings for long-circulating nanoparticles. Pharm Res 2008;25(1):55-71
   PubMed Web of Science ®Google Scholar
• Gabizon A, Chisin R, Amselem S, et al. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br J Cancer 1991;64(6):1125-32
   PubMed Web of Science ®Google Scholar
• Bridgewater LP. DOXIL (doxorubicin HCl liposome injection) Product Information. Tibotec Therapeutics/Division of Ortho Biotech Products; New Jersey: 2005
   Google Scholar
• Bogner JR, Kronawitter U, Rolinski B, et al. Liposomal doxorubicin in the treatment of advanced aids-related kaposi sarcoma. J Acquir Immune Defic Syndr 1994;7(5):463-8
   PubMed Web of Science ®Google Scholar
• Cheong C, Matos I, Choi JH, et al. Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. Cell 2010;143(3):416-29
   PubMed Web of Science ®Google Scholar
• Ogi C, Aruga A. Immunological monitoring of anticancer vaccines in clinical trials. Oncoimmunology 2013;2(8):e26012; 1-8
   PubMed Web of Science ®Google Scholar
• Tacken PJ, de Vries IJ, Torensma R, et al. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007;7(10):790-802
   PubMed Web of Science ®Google Scholar
• Lee KD, Nir S, Papahadjopoulos D. Quantitative analysis of liposome-cell interactions in vitro: rate constants of binding and endocytosis with suspension and adherent J774 cells and human monocytes. Biochemistry 1993;32(3):889-99
   PubMed Web of Science ®Google Scholar
• Miller CR, Bondurant B, McLean SD, et al. Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry 1998;37(37):12875-83
   PubMed Web of Science ®Google Scholar
• Karathanasis E, Geigerman CM, Parkos CA, et al. Selective targeting of nanocarriers to neutrophils and monocytes. Ann Biomed Eng 2009;37(10):1984-92
   PubMed Web of Science ®Google Scholar
• Pires P, Simoes S, Nir S, et al. Interaction of cationic liposomes and their DNA complexes with monocytic leukemia cells. Biochim Biophys Acta 1999;1418(1):71-84
   PubMed Web of Science ®Google Scholar
• Schwendener RA, Lagocki PA, Rahman YE. The effects of charge and size on the interaction of unilamellar liposomes with macrophages. Biochim Biophys Acta 1984;772(1):93-101
   PubMed Web of Science ®Google Scholar
• Zhang C, Tang N, Liu X, et al. siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J Control Release 2006;112(2):229-39
   PubMed Web of Science ®Google Scholar
• Semple SC, Akinc A, Chen J, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010;28(2):172-6
   PubMed Web of Science ®Google Scholar
• Filion MC, Phillips NC. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta 1997;1329(2):345-56
   PubMed Web of Science ®Google Scholar
• Christensen D, Korsholm KS, Andersen P, et al. Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines 2011;10(4):513-21
   PubMed Web of Science ®Google Scholar
• Smith DM, Simon JK, Baker JR. Applications of nanotechnology for immunology. Nat Rev Immunol 2013;13:592-605
   PubMed Web of Science ®Google Scholar
• Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res 2007;13(15 Pt 2):s4652-4
   PubMed Web of Science ®Google Scholar
• Bal SM, Hortensius S, Ding Z, et al. Co-encapsulation of antigen and toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination. Vaccine 2011;29(5):1045-52
   PubMed Web of Science ®Google Scholar
• Chen W, Huang L. Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine. Mol Pharm 2008;5(3):464-71
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Yeldandi V, McEvoy M, et al. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin b (ambisome) in neutropenic patients. Antimicrob Agents Chemother 1998;42(9):2391-8
   PubMed Web of Science ®Google Scholar
• Kager L, Pötschger U, Bielack S. Review of mifamurtide in the treatment of patients with osteosarcoma. Ther Clin Risk Manag 2010;6:279-86
   PubMed Web of Science ®Google Scholar
• Juliano RL, Stamp D. The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs. Biochem Biophys Res Commun 1975;63(3):651-8
   PubMed Web of Science ®Google Scholar
• Fidler IJ, Barnes Z, Fogler WE, et al. Involvement of macrophages in the eradication of established metastasis following intravenous injection of liposomes containing macrophages activators. Cancer Res 1982;42(2):496-501
   PubMed Web of Science ®Google Scholar
• Jain S, Mishra V, Singh P, et al. Rgd-anchored magnetic liposomes for monocytes/neutrophils-mediated brain targeting. Int J Pharm 2003;261(1-2):43-55
   PubMed Web of Science ®Google Scholar
• Bourquin C, Hotz C, Noerenberg D, et al. Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance. Cancer Res 2011;71(15):5123-33
   PubMed Web of Science ®Google Scholar
• Dovedi SJ, Melis MH, Wilkinson RW, et al. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood 2013;121(2):251-9
   PubMed Web of Science ®Google Scholar
• Cros J, Cagnard N, Woollard K, et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010;33(3):375-86
   PubMed Web of Science ®Google Scholar
• Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010;116(16):74-80
   PubMed Web of Science ®Google Scholar
• Chan M, Hayashi T, Kuy CS, et al. Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates. Bioconjug Chem 2009;20(6):1194-200
   PubMed Web of Science ®Google Scholar